Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
doripenum · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| doripenum | DRUG | - |
Inclusion Criteria: * Diagnosis of complicated lower urinary tract infection or pyelonephritis Exclusion Criteria: * Women who are pregnant, nursing or of child-bearing potential and not using a medically accepted, effective method of birth control * History of moderate or severe hypersensitivity...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 2 | PHASE1 | Gepotidacin |
| CorMedix Inc. | CRMD | 1 | PHASE2 | Meropenem-Vaborbactam, Antibiotics |
| Pfizer Inc. | PFE | 1 | - | Undisclosed |
| QIAGEN NV | QGEN | 1 | - | Undisclosed |
Doripenum is an investigational small molecule being studied for the treatment of complicated lower urinary tract infections and pyelonephritis, a type of urinary tract infection. It is in Phase 3 clinical development for these infectious disease indications.
Doripenum is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ. The drug is currently in Phase 3 clinical development for urinary tract infections.
Doripenum is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy for treating urinary tract infections.
Doripenum has one completed Phase 3 clinical trial, identified as NCT00229021, which studied the drug in the treatment of complicated lower urinary tract infection or pyelonephritis. The trial enrolled 741 participants and was randomized and double-blind.
Doripenum is the name used in the clinical trial data for this drug, which is a carbapenem antibiotic. The drug is being developed by Johnson & Johnson for the treatment of urinary tract infections, including pyelonephritis.